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Clindamycin-
Resistant Clone of 
Clostridium difﬁ  cile 
PCR Ribotype 
027, Europe
To the Editor: Since 2003, out-
breaks of Clostridium difﬁ  cile–as-
sociated disease (CDAD) associated 
with the emergence of a hypervirulent 
strain have been reported worldwide 
(1,2; www.eurosurveillance.org/em/
v12n06/1206-221.asp). This strain has 
been associated with increased dis-
ease severity and attributable mortal-
ity. Patients infected with C. difﬁ  cile 
027 fail to respond to metronidazole 
therapy (1). Several typing methods 
have been applied to further charac-
terize  C. difﬁ  cile PCR ribotype-027, 
including pulsed-ﬁ  eld gel electropho-
resis (PFGE) (North American pulsed 
ﬁ  eld type 1) and restriction enzyme 
analysis (REA) (BI). PFGE and REA 
are widely used in the United States; 
PCR ribotyping is more commonly 
used throughout Europe. More re-
cently, 2 multiple-locus variable-num-
ber tandem-repeat analysis (MLVA) 
protocols have been applied to type 
C. difﬁ  cile, and these proved more 
discriminatory compared to other 
methods (3,4). Furthermore, MLVA 
can subgroup geographically diverse 
027 isolates (G. Killgore et al., unpub 
data) as well as 027 isolates that are 
common to 1 institution (5).
We reported a case of C. difﬁ  cile 
PCR 027 in Ireland, where the isolate 
had an identical antibiogram proﬁ  le 
compared with those strains reported 
across Europe (6,7) (i.e., resistant to 
ﬂ   uoroquinolones and erythromycin, 
susceptible to clindamycin). We have 
subsequently identiﬁ  ed  C. difﬁ  cile 
027 in 6 more healthcare settings. To 
date >100 Irish C. difﬁ  cile 027 isolates 
have been characterized by analysis of 
their antibiogram proﬁ  les, toxinotyp-
ing, and 16S–23S rDNA PCR ribotyp-
ing. All C. difﬁ  cile 027 isolates were 
resistant to moxiﬂ  oxaxin, gatiﬂ  oxacin, 
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ciproﬂ   oxacin (MIC >32 mg/L), and 
erythromycin (MIC >256 mg/L) but 
susceptible to metronidazole (MIC   
0.25 mg/L) and vancomycin (MIC 
>0.5 mg/L). Clindamycin suscepti-
bility varied between isolates from 
unrelated institutions. Isolates from 2 
healthcare settings were susceptible to 
clindamycin (n = 11: MIC90  4 mg/L). 
However, clindamycin-resistant PCR 
027 isolates (n = 96: MIC90 >256 
mg/L) were identiﬁ  ed in the other 5 
healthcare institutions. All clindamy-
cin-resistant PCR 027 isolates were 
positive for the ermB gene, encoding 
the macrolide-lincosamide-strepto-
gramin-B genotype.
A subset of clindamycin-sensitive 
and -resistant Irish 027 strains isolated 
throughout 2006 (n = 22) were fur-
ther characterized by using a recently 
described MLVA protocol (3). Six 
clindamycin-susceptible isolates were 
selected from 2 healthcare settings. 
One hospital conducted active routine 
laboratory surveillance and molecular 
genotyping (n = 3). The second hos-
pital submitted only random isolates 
(n = 3) for typing during a C. dif-
ﬁ  cile outbreak. Sixteen clindamycin-
resistant PCR 027 isolates were also 
included in the MLVA. Resistant iso-
lates were selected from 5 healthcare 
settings. These included isolates from 
2 C. difﬁ  cile outbreaks with ongoing 
laboratory surveillance (n = 5, n = 6, 
respectively); a third hospital with on-
going laboratory surveillance (n = 3) 
and 2 hospitals that each submitted fe-
cal samples from patients with severe 
cases of C. difﬁ  cile disease (n = 1). 
The Stoke-Mandeville control strain 
R20291 was included for comparison.
MLVA determined that all strains 
within the clindamycin-resistant clus-
ter were closely related and were 
single- or double-locus variants with 
a maximum 5 summed tandem-re-
peat difference (STRD). In contrast, 
the closest relationship between the 
clindamycin-resistant and the clin-
damycin-sensitive clusters was a tri-
ple-locus variant with an STRD of 17. 
The nonrelated reference strain of the 
Stoke-Mandeville outbreak (R20291) 
differed considerably from all Irish 
isolates but was more related to the 
clindamycin-sensitive cluster than to 
the clindamycin-resistant cluster (Fig-
ure). We thus linked a deﬁ  ned genetic 
marker with the clindamycin-resistant 
phenotype in C. difﬁ  cile PCR-027. 
MLVA could clearly differentiate 
clindamycin-resistant and -susceptible 
isolates from the same geographic re-
gion and subgrouped them into 2 dis-
tinct clusters (Figure).
Although high-level resistance to 
ﬂ   uoroquinolone antimicrobial agents 
has been well documented in PCR 027 
(1,6), resistance to clindamycin is rare. 
Subsequently, clindamycin has been 
considered as a “protective” antimi-
crobial agent for the development of 
CDAD in an epidemiologic survey in 
the Netherlands (8). Currently, resis-
tance to this agent in NAP 1/PCR 027 
has been restricted to the United States. 
McDonald and colleagues reported that 
19 (79%) of 24 NAP 1 isolates were 
classiﬁ  ed as less susceptible (MIC 4 
mg/L) or resistant (MIC 8 mg/L) to clin-
damycin when Clinical and Laboratory 
Standards Institute criteria were used 
(2). Unfortunately, MIC values were 
not reported, and the corresponding re-
sistance genes were not investigated. In 
contrast, Canadian studies to date have 
not reported clindamycin resistance in 
this strain type. The MIC90 of Canadian 
NAP 1 isolates for clindamycin was 4 
mg/L (9,10). Although outbreaks and 
sporadic cases of PCR 027 have been 
identiﬁ   ed in several European coun-
tries, to date no clindamycin-resistant 
clone has been reported.
Detection of clindamcyin-resistant 
C. difﬁ  cile PCR 027 strains is an im-
portant and worrying development. Re-
sistance to this antimicrobal agent in-
creases the risk for CDAD in patients, 
and its use may be an important fac-
tor contributing to the persistence and 
spread of PCR 027. A similar feature 
has already been observed when ﬂ  uo-
roquinolones and cephalosporins are 
prescribed. Clindamcyin-resistant PCR 
Figure. Minimal spanning tree of 23 Clostridium difﬁ  cile isolates. In the circles, the 
individual isolates are mentioned. The numbers between the circles represent the summed 
tandem repeat differences (STRDs) between multiple-locus variable-number tandem-
repeat analysis types. Straight lines represent single-locus variants, dashed lines double-
locus variants. Curved lines represent triple-locus variants. Two related clusters can be 
discriminated: the light gray cluster (isolates B1, B4, M246, B6, and M216) and the cluster 
within dotted lines (isolates V6–44, V6–142, V6–81, 1ML, C1, 4108, V6–35, V6–80, L1, 
2191cc, C4, C8, 3ML, C44, C37, and 13ML) The isolates in the light gray cluster are 
sensitive to clindamycin; isolates in the cluster surrounded by dotted lines are resistant. 
Two isolates (M278 and R20291) did not belong to a cluster but were more related to the 
sensitive cluster than to the resistant cluster. Genetically related clusters were deﬁ  ned by 
an STRD <10.LETTERS
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027 probably reﬂ   ects the emergence 
of a new clone because MLVA clearly 
differentiates between clindamycin-
susceptible and -resistant isolates.
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Increasing 
Incidence of 
Clostridium 
difﬁ  cile–associated 
Disease, Singapore
To the Editor:  Clostridium dif-
ﬁ  cile–associated disease (CDAD) has 
increased in incidence across North 
America and Europe (1). Recent re-
ports document the emergence of an 
epidemic strain of C. difﬁ  cile, NAP1/
BI/027, associated with increased vir-
ulence (2,3). However, less informa-
tion is available regarding CDAD epi-
demiology in Asia. We examined the 
incidence of C. difﬁ  cile among hos-
pitalized patients in Singapore from 
2001 through 2006 and conducted a 
case–control study to evaluate risk 
factors for testing positive for C. dif-
ﬁ  cile toxin (CDT) in our population.
Tan Tock Seng Hospital (TTSH) 
is a 1,200-bed, acute-care general hos-
pital in Singapore that serves an urban 
population of 4 million. We calculated 
CDAD incidence using the number of 
patients testing positive for CDT per 
10,000 patient days from 2001 through 
2006. We used this calculation because 
CDT testing would have been ordered 
for clinical indications. CDT testing 
was performed by using the same 
ELISA (Premier Toxins A&B; Merid-
ian Bioscience, Inc., Cincinnati, OH, 
USA) throughout the entire period of 
investigation.
Case-patients and controls were 
selected from patients hospitalized at 
TTSH from January 1 through Decem-
ber 31, 2004. Microbiology laboratory 
records were used to deﬁ  ne 3 groups. 
Case-patients were deﬁ   ned as CDT-
positive inpatients (group 1). Two sets 
of negative controls were deﬁ  ned: the 
ﬁ   rst (group 2) consisted of patients 
who tested negative for CDT. How-
ever, because false-negatives could 
nullify differences between groups 1 
and 2, we deﬁ  ned a second set of neg-
ative controls (group 3) from among 
18,000 inpatients not tested for CDT. 
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